Últimas noticias sobre Pro-Dex (NASDAQ:PDEX) Bolsa

Pro-Dex

Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.

Pro-Dex Inc

Polkadex

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Ascendiant Capital raised Pro-Dex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) price target from $54 to $56. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Pro-Dex shares closed at $46.24 on Friday. <a href="https://www.benzinga.com/quote/PDEX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. slashed the price target for Unity Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) from $4 to $2. HC Wainwright &amp; Co. analyst Matthew Caufield downgraded the stock from Buy to Neutral. Unity Biotechnology shares closed at $0.7790 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/UBX/analyst-ratings">view this stock</a>.</li>
<li>JMP Securities cut Churchill Downs Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) price target from $144 to $138. JMP Securities analyst Jordan Bender maintained a Market Outperform rating. Churchill Downs shares closed at $93.24 on Friday. See how other <a href="https://www.benzinga.com/quote/CHDN/analyst-ratings">analysts view this stock</a>.</li>
<li>JMP Securities increased the price target for DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) from $15 to $21. JMP Securities analyst Jonathan Wolleben maintained a Market Outperform rating. DBV Technologies shares closed at $8.41 on Friday. <a href="https://www.benzinga.com/quote/DBVT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group increased the price target for Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from $85 to $100. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar General shares closed at $101.39 on Friday. See how other <a href="https://www.benzinga.com/quote/DG/analyst-ratings">analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) price target from $30 to $14. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Prothena shares settled at $6.58 on Friday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group increased Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $82 to $95. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar Tree shares closed at $88.17 on Friday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim cut Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) price target from $155 to $115. Guggenheim analyst Robert Drbul maintained a Buy rating. Target shares closed at $94.29 on Friday.  <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital cut the price target for Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from $40 to $18. Chardan Capital analyst Rudy Li maintained a Buy rating. Prothena shares settled at $6.58 on Friday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) price target from $68 to $74. Wells Fargo analyst Tiago Fauth maintained an Overweight rating. PTC Therapeutics shares closed at $45.93 on Friday. <a href="https://www.benzinga.com/quote/PTCT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PTCT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-1024x582.png" alt="" class="wp-image-928475" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

News

Price Target

Markets

Analyst Ratings

Trading Ideas

CHDN

DBVT

DLTR

PDEX

PRTA

PTCT

PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday

Ascendiant Capital analyst Edward Woo maintains Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) with a Buy and raises the price target from $54 to $56.

Ascendiant Capital Maintains Buy on Pro-Dex, Raises Price Target to $56

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock moved upwards by 228.7% to $0.83 during Friday's regular session. The company's market cap stands at $33.1 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock moved upwards by 73.84% to $0.7. The company's market cap stands at $7.9 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares moved upwards by 47.32% to $1.27. The market value of their outstanding shares is at $23.4 million. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares increased by 33.41% to $9.82. The market value of their outstanding shares is at $1.4 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares increased by 31.79% to $2.98. The market value of their outstanding shares is at $174.4 million. As per the press release, Q1 earnings came out today. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares rose 25.22% to $0.42. The company's market cap stands at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock fell 35.0% to $43.75 during Friday's regular session. The company's market cap stands at $142.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares decreased by 22.95% to $4.21. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) stock decreased by 21.0% to $14.41. The company's market cap stands at $1.8 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 19.49% to $62.0. The market value of their outstanding shares is at $806.7 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares decreased by 15.28% to $6.1. The company's market cap stands at $3.2 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock declined by 15.19% to $0.23. The company's market cap stands at $10.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADPT

AIRS

ARDX

BIVI

HCTI

NDRA

PLRZ

RSLS

12 Health Care Stocks Moving In Friday's Intraday Session

WIIM

Pro-Dex shares are trading lower after the company reported worse-than-expected Q3 sales results.

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.47 by 108.51 percent. This is a 415.79 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $17.41 million which missed the analyst consensus estimate of $17.70 million by 1.62 percent. This is a 21.84 percent increase over sales of $14.29 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Pro-Dex Q3 EPS $0.98 Beats $0.47 Estimate, Sales $17.41M Miss $17.70M Estimate

Pro-Dex shares are trading lower. The company reported Q2 financial results.

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.38 by 60.53 percent. This is a 335.71 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $16.79 million which beat the analyst consensus estimate of $13.80 million by 21.69 percent. This is a 33.40 percent increase over sales of $12.59 million the same period last year.

Pro-Dex Q2 EPS $0.61 Beats $0.38 Estimate, Sales $16.79M Beat $13.80M Estimate

A significant insider transaction involving the exercise of company stock options was reported on November 25, by Angelita Domingo, Board Member at Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>), as per the latest SEC filing.
What Happened: The latest Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0000788920/000107997324001635//Archives/edgar/data/788920/000107997324001635/0001079973-24-001635-index.htm">U.S. Securities and Exchange Commission</a> uncovered Domingo, Board Member at Pro-Dex, exercising stock options for 4,250 shares of PDEX. The total transaction was valued at $78,412.
Pro-Dex shares are currently trading down by 6.63%, with a current price of $45.75 as of Tuesday morning. This brings the total value of Domingo's 4,250 shares to $78,412.
<h3>Delving into Pro-Dex's Background</h3>
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
<h3>Pro-Dex: Financial Performance Dissected</h3>
Revenue Growth: Pro-Dex's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 24.74%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a low gross margin of 34.58%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Pro-Dex's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.76.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 0.47, Pro-Dex faces challenges in effectively managing its debt levels, indicating potential financial strain.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 32.24, Pro-Dex's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.03, Pro-Dex's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 19.49 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Exploring Key Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000788920">Check Out The Full List Of Pro-Dex's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Options Movement At Pro-Dex: Angelita Domingo Exercises Worth $78K

Pro-Dex shares are trading higher after Ascendiant Capital maintained a Buy rating on the stock and raised its price target from $30 to $52.

Ascendiant Capital analyst Edward Woo maintains Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) with a Buy and raises the price target from $30 to $52.

Ascendiant Capital Maintains Buy on Pro-Dex, Raises Price Target to $52

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 50.3% to $0.64 during Friday's regular session. The market value of their outstanding shares is at $24.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 45.55% to $5.08. The market value of their outstanding shares is at $385.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares rose 27.44% to $1.86. The company's market cap stands at $2.5 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares rose 26.41% to $1.11. The company's market cap stands at $4.0 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 25.53% to $38.94. The market value of their outstanding shares is at $130.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) stock increased by 20.73% to $14.88. The market value of their outstanding shares is at $1.2 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 35.1% to $1.26 during Friday's regular session. The market value of their outstanding shares is at $457.2 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 22.44% to $11.1. The market value of their outstanding shares is at $12.7 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 21.57% to $17.23. The company's market cap stands at $1.5 billion. </li>
<li>Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) stock fell 14.0% to $14.99. The market value of their outstanding shares is at $918.7 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 13.42% to $1.06. The company's market cap stands at $5.9 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 12.38% to $0.5. The market value of their outstanding shares is at $36.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

ATHA

BFRI

CDXC

ALPS ETF Trusthen & Steers Global Realty Majors ETF

LXRX

MYGN

PLSE

TOVX

XAIR

<h3>Gainers</h3>
<ul>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares increased by 66.0% to $4.4 during Friday's pre-market session. The company's market cap stands at $86.8 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock rose 43.83% to $2.1. The market value of their outstanding shares is at $2.8 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares rose 26.13% to $0.54. The market value of their outstanding shares is at $20.6 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 18.06% to $36.62. The company's market cap stands at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares rose 16.79% to $6.26. The market value of their outstanding shares is at $230.5 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock moved upwards by 16.04% to $4.05. The market value of their outstanding shares is at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock declined by 10.37% to $0.77. The company's market cap stands at $18.3 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 9.76% to $1.11. The company's market cap stands at $6.1 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares decreased by 8.07% to $0.57. The market value of their outstanding shares is at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

Envoy Medical, Inc. - Class A Common Stock

COCH

MOLN

MTNB

ONMD

TRIB

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock moved upwards by 66.0% to $4.4 during Friday's pre-market session. The market value of their outstanding shares is at $86.8 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 43.83% to $2.1. The company's market cap stands at $2.8 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock increased by 26.13% to $0.54. The company's market cap stands at $20.6 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 18.06% to $36.62. The market value of their outstanding shares is at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 16.79% to $6.26. The company's market cap stands at $230.5 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 16.04% to $4.05. The company's market cap stands at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) stock decreased by 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 10.37% to $0.77. The market value of their outstanding shares is at $18.3 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares declined by 9.76% to $1.11. The market value of their outstanding shares is at $6.1 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares fell 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock declined by 8.07% to $0.57. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Pro-Dex shares are trading higher after the company reported better-than-expected Q1 financial results.

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.29 by 158.62 percent. The company reported quarterly sales of $14.892 million which beat the analyst consensus estimate of $12.100 million by 23.07 percent. This is a 24.74 percent increase over sales of $11.938 million the same period last year.

Pro-Dex Q1 2025 GAAP EPS $0.75 Beats $0.29 Estimate, Sales $14.892M Beat $12.100M Estimate

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 28.5% to $0.55 during Thursday's after-market session. The market value of their outstanding shares is at $21.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 28.08% to $1.87. The company's market cap stands at $2.5 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 19.69% to $37.13. The market value of their outstanding shares is at $124.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock increased by 18.62% to $4.14. The market value of their outstanding shares is at $314.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 7.7% to $54.49. The company's market cap stands at $6.9 billion. The company's, Q3 earnings came out today. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares rose 7.49% to $6.31. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock decreased by 10.6% to $1.1 during Thursday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock decreased by 5.74% to $1.47. The market value of their outstanding shares is at $10.1 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock decreased by 5.52% to $2.57. The company's market cap stands at $3.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 5.49% to $7.75. The company's market cap stands at $18.6 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.23% to $0.83. The company's market cap stands at $28.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock decreased by 5.12% to $1.67. The market value of their outstanding shares is at $15.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRTX

HALO

LUCY

OCEA

PALI

12 Health Care Stocks Moving In Thursday's After-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Ascendiant Capital raised the price target for Pro-Dex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) from $28 to $30. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Pro-Dex shares gained 4.2% to close at $23.28 on Friday. <a href="https://www.benzinga.com/quote/PDEX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. boosted the price target for Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) from $16 to $30. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Summit Therapeutics shares fell 1.8% to close at $12.27 on Friday. <a href="https://www.benzinga.com/quote/MEI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) price target from $40 to $42. JP Morgan analyst Bill Peterson upgraded the stock from Neutral to Overweight. United States Steel shares gained 4.3% to close at $31.27 on Friday. <a href="https://www.benzinga.com/quote/SMMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) price target from $855 to $950. Morgan Stanley analyst Simeon Gutman maintained an Overweight rating. Costco shares fell 1.1% to close at $876.68 on Friday. <a href="https://www.benzinga.com/quote/COST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush boosted the price target for LGI Homes, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) from $97 to $125. Wedbush analyst Jay McCanless upgraded the stock from Underperform to Neutral. LGI Homes shares rose 0.8% to close at $104.80 on Friday. <a href="https://www.benzinga.com/quote/LGIH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BTIG increased Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) price target from $47 to $51. BTIG analyst Clark Lampen maintained a Buy rating. Roblox shares fell 0.2% to close at $43.64 on Friday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) price target from $3 to $6. B of A Securities analyst Andrew Didora upgraded the stock from Underperform to Neutral. JetBlue shares fell 1.7% to close at $5.30 on Friday. S<a href="https://www.benzinga.com/quote/JBLU/analyst-ratings">ee how other analysts view this stock.</a></li>
<li>Deutsche Bank increased the price target for Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) from $107 to $109. Deutsche Bank analyst Steve Powers downgraded the stock from Buy to Hold. Colgate-Palmolive shares fell 0.6% to close at $107.86 on Friday. See how other analysts view this stock.</li>
<li>JP Morgan boosted Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) price target from $170 to $174. JP Morgan analyst Bill Peterson upgraded the stock from Neutral to Overweight. Nucor shares fell 0.6% to close at $138.79 on Friday. <a href="https://www.benzinga.com/quote/NUE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital boosted Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) price target from $100 to $110. BMO Capital analyst Andrew Strelzik maintained an Outperform rating. Starbucks shares fell 0.5% to close at $91.15 on Friday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SBUX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="506" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-1024x506.png" alt="" class="wp-image-537416" style="width:621px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-1024x506.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09085953/image-70.png 1368w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Pre-Market Outlook

COST

JBLU

LGIH

RBLX

SBUX

SMMT

Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday

Ascendiant Capital analyst Edward Woo maintains Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) with a Buy and raises the price target from $28 to $30.

Ascendiant Capital Maintains Buy on Pro-Dex, Raises Price Target to $30

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.35 by 31.43 percent. This is a 9.52 percent increase over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $15.03 million which beat the analyst consensus estimate of $10.60 million by 41.75 percent. This is a 41.23 percent increase over sales of $10.64 million the same period last year.

Pro-Dex Q4 EPS $0.46 Beats $0.35 Estimate, Sales $15.03M Beat $10.60M Estimate

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.35 by 45.71 percent. This is a 47.22 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $14.29 million which beat the analyst consensus estimate of $13.20 million by 8.28 percent. This is a 9.28 percent increase over sales of $13.08 million the same period last year.

Pro-Dex Q3 EPS $0.19 Misses $0.35 Estimate, Sales $14.29M Beat $13.20M Estimate

Press Releases

Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

Pro-Dex, Inc. Announces Fiscal 2025 Second Quarter and Six-Month Results

Pro-Dex, Inc. Announces Fiscal 2025 Third Quarter and Nine-Month Results

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies Glb

BioSig Technologies

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CVRx

Electromed

Fonar

Fractyl Health

Inogen

Kewaunee Scientific Corporation - Common Stock

Kewaunee Scientific

KORU Medical Systems, Inc. - Common Stock

KORU Medical Systems

LENSAR

Lucid Diagnostics

Pulmonx

Microbot Medical

Monogram Technologies Inc. - Common Stock

Monogram Technologies

Myomo

Orchestra BioMed Holdings, Inc. - Ordinary Shares

Orchestra BioMed Hldgs

Odysight ai

Owlet

Profound Medical

Sight Sciences

Neuronetics

Stereotaxis

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International

Ascendiant Capital

Comments

Pro-Dex

Noticias

Últimas noticias sobre Pro-Dex (NASDAQ:PDEX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL